drugset
drugset / Trial / NCT01025570

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

NCT01025570 ↗

Phase 1 Terminated 3 enrolled University of California, San Francisco University of Utah · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.

Timeline

Start
2010-05
Primary completion
2012-05
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosutinib Small molecule 400 mg Oral
Subject Gemcitabine Small molecule 1000 mg/m2 —

Indications

pancreatic adenocarcinoma